✦ LIBER ✦

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma

✍ Scribed by ReikoF. Irie; DavidW. Ollila; Steven O’Day; DonaldL. Morton

Book ID: 105966686
Publisher: Springer-Verlag
Year: 2003
Tongue: English
Weight: 776 KB
Volume: 53
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-003-0436-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of anti-GD3 ganglioside

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma

✍ Lori M. Minasian; Tzy Jyun Yao; Thomas A. Steffens; David A. Scheinberg; Linda W 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Phase I trial of subcutaneous recombinan

Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma

✍ Omar Eton; Michael G. Rosenblum; Sewa S. Legha; Wehei Zhang; Mary Jo East; Agop 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 3 views

## Abstract ## BACKGROUND Interleukin‐2 (IL‐2) has activity in metastatic melanoma when given in high doses by the intravenous (IV) route, but its side effects and effectiveness when given in intermediate to high doses by the subcutaneous (SC) route have not been studied adequately. This study sou

218 POSTER Phase I/II study of CNTO 95,

218 POSTER Phase I/II study of CNTO 95, a fully human monoclonal antibody (mAb) to alpha-v integrins, in patients with metastatic melanoma

✍ S. O' Day; J. Richards; T. Jiao; M. Mata; U. Prabhakar; R. Beckman; Z. Lang; A. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 377 KB

A clinical phase I/II trial with the mon

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

✍ M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

30 A phase I clinical trial of HGS-ETR1,

30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors

✍ R.B. Cohen; N.J. Meropol; K.M. Padavic; N.L. Fox; A. Corey; M. Fleming; M. Mita; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Phase II Trial of a Toll-Like Receptor 9

Phase II Trial of a Toll-Like Receptor 9-Activating Oligonucleotide in Patients With Metastatic Melanoma

✍ Pashenkov, M.; Goess, G.; Wagner, C.; Hormann, M.; Jandl, T.; Moser, A.; Britten 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 777 KB